At a glance
ClinicalIndex Comparison RecordN/ACompleted· 66 enrolled
Drug / intervention
Best Supportive Care +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase III Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases
In Brief
A clinical study evaluating Best Supportive Care and Palliative Radiation Therapy for Hepatocellular Carcinoma and Liver Metastases. Completed, enrolled 66 participants across 7 sites.
Detailed Summary
The purpose of this study is to see whether one dose of palliative radiation therapy directed to the liver in combination with standard BSC might help to reduce liver pain/discomfort due to cancer when compared to getting standard BSC alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma, Liver Metastases
CountriesCanada
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartDec 2015
Primary CompletionOct 2022
Study CompletionOct 2024
TodayJul 2026
First PostedJul 30, 2015
Enrollment StartDec 11, 2015
Primary CompletionOct 26, 2022
Study CompletionOct 2, 2024
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 10.9 years ago
Interventions
Best Supportive Careother
Including analgesics, palliative care and/or pain specialist assessment as needed
Palliative Radiation Therapyradiation
8 Gy in 1 fraction in whole liver or near whole liver. Including anti-emetic pre-medications